KR102630575B1 - Ido 억제제의 무정형 및 결정질 형태 - Google Patents

Ido 억제제의 무정형 및 결정질 형태 Download PDF

Info

Publication number
KR102630575B1
KR102630575B1 KR1020207002491A KR20207002491A KR102630575B1 KR 102630575 B1 KR102630575 B1 KR 102630575B1 KR 1020207002491 A KR1020207002491 A KR 1020207002491A KR 20207002491 A KR20207002491 A KR 20207002491A KR 102630575 B1 KR102630575 B1 KR 102630575B1
Authority
KR
South Korea
Prior art keywords
compound
fluoroquinolin
cyclohexyl
cancer
propanamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207002491A
Other languages
English (en)
Korean (ko)
Other versions
KR20200020916A (ko
Inventor
제이 패트릭 파워스
힐러리 플레이크 벡
막심 오시포브
모린 케이 라일리
헌터 폴 슈나토나
제임스 로스 워커
미하일 지빈스키
타마르 로젠바움
이안 스콧 영
제니퍼 넬슨
페틴카 블라호바
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20200020916A publication Critical patent/KR20200020916A/ko
Application granted granted Critical
Publication of KR102630575B1 publication Critical patent/KR102630575B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020207002491A 2017-06-30 2018-06-29 Ido 억제제의 무정형 및 결정질 형태 Active KR102630575B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762527855P 2017-06-30 2017-06-30
US62/527,855 2017-06-30
PCT/US2018/040262 WO2019006283A1 (en) 2017-06-30 2018-06-29 AMORPHOUS AND CRYSTALLINE FORMS OF IDO INHIBITORS

Publications (2)

Publication Number Publication Date
KR20200020916A KR20200020916A (ko) 2020-02-26
KR102630575B1 true KR102630575B1 (ko) 2024-01-29

Family

ID=64742242

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207002491A Active KR102630575B1 (ko) 2017-06-30 2018-06-29 Ido 억제제의 무정형 및 결정질 형태

Country Status (12)

Country Link
US (2) US11236049B2 (https=)
EP (1) EP3644993B1 (https=)
JP (1) JP7690284B2 (https=)
KR (1) KR102630575B1 (https=)
CN (1) CN111093651B (https=)
AU (1) AU2018294314B2 (https=)
CA (1) CA3066789A1 (https=)
EA (1) EA202090119A1 (https=)
IL (1) IL271601B2 (https=)
MX (2) MX391848B (https=)
SG (1) SG11201911937UA (https=)
WO (1) WO2019006283A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7315483B2 (ja) * 2017-06-30 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法
EP4426022A3 (en) * 2017-11-17 2024-11-20 Telefonaktiebolaget LM Ericsson (publ) Signaling ta-offset in nr
CN110357813A (zh) * 2018-04-09 2019-10-22 信达生物制药(苏州)有限公司 一种新型吲哚胺2,3-双加氧酶抑制剂及其制备方法和用途
WO2020000236A1 (zh) * 2018-06-27 2020-01-02 深圳仁泰医药科技有限公司 (r)-n-(4-氯苯基)-2-(顺-4-(6-氟喹啉-4-基)环己基)丙酰胺的晶型
WO2021050653A1 (en) * 2019-09-11 2021-03-18 Bristol-Myers Squibb Company Pharmaceutical formulations of indoleamine 2, 3-dioxygenase inhibitors
BR112022009944A2 (pt) * 2019-11-26 2022-08-09 Bristol Myers Squibb Co Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida
AR120935A1 (es) * 2020-01-02 2022-03-30 Hutchison Medipharma Ltd Derivados de amida y usos de los mismos

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073770A1 (en) * 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8450351B2 (en) 2005-12-20 2013-05-28 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
WO2008036642A2 (en) 2006-09-19 2008-03-27 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
WO2009156652A1 (fr) 2008-05-29 2009-12-30 Saint-Gobain Centre De Recherches Et D'etudes Europeen Structure en nid d'abeille a base de titanate d'aluminium
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
NO2694640T3 (https=) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
JP7315483B2 (ja) 2017-06-30 2023-07-26 ブリストル－マイヤーズ スクイブ カンパニー 置換キノリニルシクロヘキシルプロパンアミド化合物および改良されたその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073770A1 (en) * 2014-11-05 2016-05-12 Flexus Biosciences, Inc. Immunoregulatory agents

Also Published As

Publication number Publication date
CA3066789A1 (en) 2019-01-03
IL271601B1 (en) 2024-01-01
IL271601B2 (en) 2024-05-01
CN111093651A (zh) 2020-05-01
EA202090119A1 (ru) 2020-04-21
US20200115342A1 (en) 2020-04-16
WO2019006283A1 (en) 2019-01-03
MX2021015656A (es) 2022-02-03
BR112019027259A2 (pt) 2020-07-14
JP7690284B2 (ja) 2025-06-10
SG11201911937UA (en) 2020-01-30
IL271601A (en) 2020-02-27
US20220169615A1 (en) 2022-06-02
JP2020526520A (ja) 2020-08-31
EP3644993B1 (en) 2023-08-02
AU2018294314B2 (en) 2024-09-19
CN111093651B (zh) 2023-06-06
EP3644993A4 (en) 2021-03-10
EP3644993A1 (en) 2020-05-06
MX2019014885A (es) 2020-02-13
US12421195B2 (en) 2025-09-23
AU2018294314A1 (en) 2020-02-06
KR20200020916A (ko) 2020-02-26
MX391848B (es) 2025-03-19
US11236049B2 (en) 2022-02-01

Similar Documents

Publication Publication Date Title
KR102630575B1 (ko) Ido 억제제의 무정형 및 결정질 형태
JP2022058400A (ja) 免疫調節剤としての複素環化合物
KR20220119458A (ko) T 세포 활성화제로서 유용한 치환된 헤테로아릴 화합물
JP2020526520A5 (https=)
KR20220119454A (ko) T 세포 활성화제로서 유용한 치환된 퀴나졸리닐 화합물
KR20220119456A (ko) T 세포 활성화제로서 유용한 치환된 퀴놀리노닐 피페라진 화합물
KR20190004743A (ko) 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
WO2023122777A1 (en) Oxime derivatives useful as t cell activators
US11203592B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
KR20210091121A (ko) 포스포이노시티드 3-키나아제 (pi3k) 억제제의 결정질 형태
WO2024254227A1 (en) Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
AU2024314878A1 (en) Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
US12527783B2 (en) Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
EA049146B1 (ru) Аморфные и кристаллические формы ido-ингибиторов
EA041037B1 (ru) Аморфные и кристаллические формы ido-ингибиторов
BR112019027259B1 (pt) Formas amorfas e cristalinas de inibidores da ido, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200123

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210629

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230721

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231130

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240124

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240124

End annual number: 3

Start annual number: 1

PG1601 Publication of registration